Literature DB >> 3960290

Delayed ischemic deterioration in patients with early aneurysm operation and intravenous nimodipine.

H Säveland, B Ljunggren, L Brandt, K Messeter.   

Abstract

A consecutive series of 100 individuals with aneurysmal subarachnoid hemorrhage were subjected to early aneurysm operation followed by subsequent intravenous administration of the calcium antagonist nimodipine during the critical period for symptomatic vasospasm. A total of 85 patients were in Hunt and Hess neurological Grades I through III, and 15 were in Grade IV or V before operation. In 39 individuals the aneurysm was located in the anterior cerebral artery complex (ACA), in 29 it originated from the internal carotid artery complex (ICA), and in 32 individuals the ruptured aneurysm arose from the middle cerebral artery (MCA). Of the patients, 71% made a good neurological recovery; the morbidity was 22%, and the mortality was 7%. Of the Grade I-III patients, 79% made a good neurological recovery, and the mortality was 6%. Delayed ischemic cerebral deterioration with permanent dysfunction occurred in five patients, all with ruptured ACA aneurysms. No single patient in the ICA or MCA populations developed delayed ischemic deterioration with fixed neurological deficit despite the presence of several potential risk factors, especially among the MCA aneurysm patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3960290     DOI: 10.1227/00006123-198602000-00005

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  12 in total

Review 1.  Aneurysmal subarachnoid hemorrhage: prevention of delayed ischemic dysfunction with intravenous nimodipine.

Authors:  B Ljunggren; L Brandt; H Säveland; B Romner; T Ryman; K E Andersson
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

2.  The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs.

Authors:  M Shibuya; Y Suzuki; M Takayasu; T Asano; T Harada; I Ikegaki; S Satoh; H Hidaka
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  Amount of subarachnoid blood and vasospasm: current aspects. A transcranial Doppler study.

Authors:  C Schaller; V Rohde; B Meyer; W Hassler
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

4.  The haemodynamic effect of transcranial Doppler-guided high-dose nimodipine treatment in established vasospasm after subarachnoid haemorrhage.

Authors:  S C Zygmunt; T J Delgado-Zygmunt
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Early aneurysm surgery: a 7 year clinical practice report.

Authors:  J M Gilsbach; A G Harders; H R Eggert; M E Hornyak
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

6.  Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage.

Authors:  D Tettenborn; L Porto; T Ryman; V Strugo; G Taquoi; R Battye
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

7.  Management of the ruptured intracranial aneurysm--early surgery, late surgery, or modulated surgery? Personal experience based upon 468 patients admitted in two periods (1972-1984 and 1985-1989).

Authors:  R Deruty; C Mottolese; I Pelissou-Guyotat; J F Soustiel
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

8.  Effects of HA1077, an intracellular calcium antagonist, on neurotransmitter metabolism in rat brain in vivo.

Authors:  Y Kondoh; S Mizusawa; M Murakami; K Nagata; H Nakamichi; K Watanabe
Journal:  Metab Brain Dis       Date:  1991-09       Impact factor: 3.584

9.  Morbidity and mortality after early aneurysm surgery--a prospective study with nimodipine prevention.

Authors:  J M Gilsbach; A G Harders
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

10.  Does the timing of aneurysm surgery neglect the real problems of subarachnoid haemorrhage?

Authors:  N Freckmann; M Noll; D Winkler; G Nowak; H Rehn; M Neuss; H D Herrmann
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.